Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome in Advanced Bone and Soft Tissue Sarcoma
NCT04900766Phase 1Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in bone sarcoma and soft tissue sarcoma (STS), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Treatment-Emergent Adverse Events. Started Aug 2021; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
bone sarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04900766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900766.